首页 > 最新文献

Japanese Journal of Leprosy最新文献

英文 中文
[Japanese guideline on thalidomide usage in the management of erythema nodosum leprosum]. [日本沙利度胺治疗麻风结节性红斑指南]。
Q4 Medicine Pub Date : 2011-09-01 DOI: 10.5025/hansen.80.275
Norihisa Ishii, Yutaka Ishida, Yoshiko Okano, Motoaki Ozaki, Masaich Gidoh, Kimiko Kumano, Masamichi Goto, Reiko Nogami, Kentaro Hatano, Akatsuki Yamada, Rie Roselyne Yotsu

Treatment of erythema nodosum leprosum (ENL, type 2 reaction) using thalidomide provides effective alternative choice to steroid therapy. Yet, the Japanese National Health Insurance approves thalidomide prescription only for the treatment of multiple myeloma under the Thalidomide Education and Risk Management System (TERMS). Benefit of thalidomide therapy for patients with ENL is already an established fact based on various reports from other countries, but limited experiences and standards in Japan have hindered application of the medication to our patients. This led us to compose a local guideline. Based on and following the TERMS, we suggest starting thalidomide from 50-100 mg/day and then onwards adjusting the dose according to the symptoms of each patient, not to exceed the maximum recommended dose of 300 mg/day, for the treatment of ENL.

使用沙利度胺治疗麻风结节性红斑(ENL, 2型反应)是类固醇治疗的有效替代选择。然而,日本国民健康保险仅根据沙利度胺教育和风险管理系统(TERMS)批准沙利度胺处方用于治疗多发性骨髓瘤。根据其他国家的各种报告,沙利度胺治疗ENL患者的益处已经是一个既定的事实,但日本有限的经验和标准阻碍了该药物在我国患者中的应用。这促使我们编写了一份本地指南。基于并遵循本条款,我们建议沙利度胺起始剂量为50- 100mg /天,然后根据每位患者的症状调整剂量,不超过最大推荐剂量300mg /天,用于ENL的治疗。
{"title":"[Japanese guideline on thalidomide usage in the management of erythema nodosum leprosum].","authors":"Norihisa Ishii,&nbsp;Yutaka Ishida,&nbsp;Yoshiko Okano,&nbsp;Motoaki Ozaki,&nbsp;Masaich Gidoh,&nbsp;Kimiko Kumano,&nbsp;Masamichi Goto,&nbsp;Reiko Nogami,&nbsp;Kentaro Hatano,&nbsp;Akatsuki Yamada,&nbsp;Rie Roselyne Yotsu","doi":"10.5025/hansen.80.275","DOIUrl":"https://doi.org/10.5025/hansen.80.275","url":null,"abstract":"<p><p>Treatment of erythema nodosum leprosum (ENL, type 2 reaction) using thalidomide provides effective alternative choice to steroid therapy. Yet, the Japanese National Health Insurance approves thalidomide prescription only for the treatment of multiple myeloma under the Thalidomide Education and Risk Management System (TERMS). Benefit of thalidomide therapy for patients with ENL is already an established fact based on various reports from other countries, but limited experiences and standards in Japan have hindered application of the medication to our patients. This led us to compose a local guideline. Based on and following the TERMS, we suggest starting thalidomide from 50-100 mg/day and then onwards adjusting the dose according to the symptoms of each patient, not to exceed the maximum recommended dose of 300 mg/day, for the treatment of ENL.</p>","PeriodicalId":35918,"journal":{"name":"Japanese Journal of Leprosy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5025/hansen.80.275","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30161010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Peculiar history to formation of 'Freely recuperate zone' in the National Sanatorium Kuryu Rakusen-en, Gunma, Japan (relation between the 'Old Yunosawa-ward' and 'Freely recuperate zone' in the National Sanatorium Kuryu Rakusen-en)]. [日本群马县久留留院“自由疗养区”形成的特殊历史(久留留院“老游野泽区”与“自由疗养区”的关系)]。
Q4 Medicine Pub Date : 2011-09-01 DOI: 10.5025/hansen.80.249
Makoto Kitahara

Hansen's disease sufferers had been visiting the hot spring, Kusatsu-Spa, in Gunma, Japan, for Toji (which means 'hot springs treatment' in Japanese) since the middle ages, as it was known reportedly for a long time to be effective in curing the disease. In 1869, Kusatsu-Spa was hit by a massive fire. The innkeepers, who suffered devastating damages, were trying to reconstruct the economy quickly by promoting the medical benefits of the hot spring. This made many Hansen's disease patients to visit and of which many stayed on a long term bases. They would use the hot spring with ordinary visitors. And, they had received the treatment of the spotted moxa cautery with the hot-spring treatment. Later on, Kusatsu- Spa became well known throughout Japan and as the numbers of ordinary visitors increased, they voiced their concerns in sharing the hot spring with the Hansen's disease patients. Therefore, the innkeepers decided to move the patients to another district called Yunosawa and suggested to make a special village of just the patients. In 1887, the representative of the patients came to an agreement with the mayor of Yunosawa to establish a treatment centre there. Yunosawa became part of an administrative area of Kusatsu Town. The area seemed to become a local-governing area mainly shaped by Hansen's disease sufferers and the first legal residential area where Hansen's disease sufferers were given citizenships and may convalesce freely. However, in 1931, leprosy prevention law was passed, and the Japanese government built a new medical treatment centre of Hansen's disease, 4km away from Kusatsu- Spa, which is called National Sanatorium Kuryu Rakusen-en. After deliberations with the representative of the Hansen's disease patients living in the Yunosawa area and the governor of Gunma Prefecture, who received the order from the Japanese government to move them, had agreed to the mass relocation in 1941. This is how Yunosawa had closed its 55 years history and many Hansen's disease patients had moved to the National Sanatorium Kuryu Rakusen-en. The 'Freely recuperate Zone' within the centre houses affluent patients who had enough funds to build their own houses. I was able to hear from many residential People who have historical knowledge of the above and would like to report it here.

自中世纪以来,麻风病患者一直到日本群马县的kusatsu温泉进行Toji(日语中的“温泉治疗”),因为据说长期以来麻风病患者都知道它能有效治疗麻风病。1869年,草津温泉遭遇了一场大火。遭受毁灭性损失的旅店老板们正试图通过宣传温泉的医疗效益来迅速重建经济。这使得许多汉森氏病患者来参观,其中许多人长期留在基地。他们会和普通游客一起泡温泉。并且,他们接受了斑点艾草灼烧与温泉治疗。后来,草津温泉在日本家喻户晓,随着普通游客的增加,他们表达了与汉森病患者分享温泉的担忧。因此,旅馆老板决定把病人转移到另一个叫做Yunosawa的地区,并建议为病人建立一个特殊的村庄。1887年,患者代表与Yunosawa市长达成协议,在那里建立一个治疗中心。Yunosawa成为草津镇行政区域的一部分。该地区似乎成为了以麻风病患者为主体的地方自治地区,也是麻风病患者获得公民权并可以自由康复的第一个合法居住区。然而,在1931年,麻风病防治法被通过,日本政府在离草津温泉4公里的地方建立了一个新的麻风病医疗中心,被称为Kuryu rakusen国立疗养院。在与Yunosawa地区麻风病患者代表和接到日本政府搬迁命令的群马县知事商议后,于1941年同意了大规模搬迁。这就是Yunosawa结束55年历史的方式,许多汉森病患者搬到了国立疗养院Kuryu rakusen。中心内的“自由休养区”容纳了富裕的病人,他们有足够的资金建造自己的房子。我从许多居民那里听到了以上的历史知识,并想在这里报告。
{"title":"[Peculiar history to formation of 'Freely recuperate zone' in the National Sanatorium Kuryu Rakusen-en, Gunma, Japan (relation between the 'Old Yunosawa-ward' and 'Freely recuperate zone' in the National Sanatorium Kuryu Rakusen-en)].","authors":"Makoto Kitahara","doi":"10.5025/hansen.80.249","DOIUrl":"https://doi.org/10.5025/hansen.80.249","url":null,"abstract":"<p><p>Hansen's disease sufferers had been visiting the hot spring, Kusatsu-Spa, in Gunma, Japan, for Toji (which means 'hot springs treatment' in Japanese) since the middle ages, as it was known reportedly for a long time to be effective in curing the disease. In 1869, Kusatsu-Spa was hit by a massive fire. The innkeepers, who suffered devastating damages, were trying to reconstruct the economy quickly by promoting the medical benefits of the hot spring. This made many Hansen's disease patients to visit and of which many stayed on a long term bases. They would use the hot spring with ordinary visitors. And, they had received the treatment of the spotted moxa cautery with the hot-spring treatment. Later on, Kusatsu- Spa became well known throughout Japan and as the numbers of ordinary visitors increased, they voiced their concerns in sharing the hot spring with the Hansen's disease patients. Therefore, the innkeepers decided to move the patients to another district called Yunosawa and suggested to make a special village of just the patients. In 1887, the representative of the patients came to an agreement with the mayor of Yunosawa to establish a treatment centre there. Yunosawa became part of an administrative area of Kusatsu Town. The area seemed to become a local-governing area mainly shaped by Hansen's disease sufferers and the first legal residential area where Hansen's disease sufferers were given citizenships and may convalesce freely. However, in 1931, leprosy prevention law was passed, and the Japanese government built a new medical treatment centre of Hansen's disease, 4km away from Kusatsu- Spa, which is called National Sanatorium Kuryu Rakusen-en. After deliberations with the representative of the Hansen's disease patients living in the Yunosawa area and the governor of Gunma Prefecture, who received the order from the Japanese government to move them, had agreed to the mass relocation in 1941. This is how Yunosawa had closed its 55 years history and many Hansen's disease patients had moved to the National Sanatorium Kuryu Rakusen-en. The 'Freely recuperate Zone' within the centre houses affluent patients who had enough funds to build their own houses. I was able to hear from many residential People who have historical knowledge of the above and would like to report it here.</p>","PeriodicalId":35918,"journal":{"name":"Japanese Journal of Leprosy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30161007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Leprosy is not a "genetic disease"]. 麻风病不是一种“遗传性疾病”。
Q4 Medicine Pub Date : 2011-04-01
K Suzuki
{"title":"[Leprosy is not a \"genetic disease\"].","authors":"K Suzuki","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":35918,"journal":{"name":"Japanese Journal of Leprosy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29838409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Symposium: How can we contribute to the world leprosy control?]. [专题讨论会:我们如何为世界麻风病控制作出贡献?]
Q4 Medicine Pub Date : 2011-04-01
Kentaro Hatano
{"title":"[Symposium: How can we contribute to the world leprosy control?].","authors":"Kentaro Hatano","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":35918,"journal":{"name":"Japanese Journal of Leprosy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29838408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Special lecture: What it means to be "infected"--how a human body, or health professionals combat "infection"]. 【特别讲座:“感染”意味着什么——人体或卫生专业人员如何对抗“感染”】。
Q4 Medicine Pub Date : 2011-04-01
Soichi Arakawa
{"title":"[Special lecture: What it means to be \"infected\"--how a human body, or health professionals combat \"infection\"].","authors":"Soichi Arakawa","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":35918,"journal":{"name":"Japanese Journal of Leprosy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29838407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Role of mycolactone in the nerve damage of Buruli ulcer (Mycobacterium ulcerans infection)]. 【霉菌内酯在布鲁里溃疡(溃疡分枝杆菌感染)神经损伤中的作用】。
Q4 Medicine Pub Date : 2011-02-01 DOI: 10.5025/hansen.80.5
Junichiro En, Norihisa Ishii, Masamichi Goto

Buruli ulcer is a skin disease caused by Mycobacterium ulcerans (M. ulcerans). In this review, we introduce our recent studies and other important works. Lesions of Buruli ulcer are usually painless, despite the extensive tissue necrosis. We have reported that mice inoculated with M ulcerans show nerve degeneration and absence of pain, but the mechanism evoking the nerve damage have not been clarified. In order to define whether mycolactone, a toxic lipid produced by M. ulcerans, can induce nerve damages, we have injected mycolactone A/B to BALB/c mouse footpads. Mycolactone induced footpad swelling, and sensory test showed hyperesthesia on day 7 and 14, recovery on day 21, and hypoesthesia on days 28 and 42. Histologically, nerve bundles showed hemorrhage, neutrophilic infiltration, and loss of Schwann cell nuclei on days 7 and 14. Semithin section studies revealed vacuolar change of Schwann cells started on day 14, which subsided by day 42, but myelinated fiber density remained low. This study suggests that mycolactone directly damages nerves and is responsible for the absence of pain characteristic of Buruli ulcer. In the human lesions, presence of neuritis is reported (Rondini S, 2006), and murine studies showed "autoamputation" (Addo P, 2005). In order to prevent the serious deformities evoked by Buruli ulcer, further studies are necessary.

布鲁里溃疡是一种由溃疡分枝杆菌引起的皮肤病。本文主要介绍了本研究的最新进展和其他重要工作。布鲁里溃疡的病变通常是无痛的,尽管有广泛的组织坏死。我们已经报道了接种M溃疡菌的小鼠表现出神经变性和无疼痛,但引起神经损伤的机制尚未明确。为了确定溃疡分枝杆菌产生的毒性脂质菌内酯是否会引起神经损伤,我们将菌内酯a /B注射到BALB/c小鼠脚垫。菌内酯诱导足垫肿胀,感觉试验显示第7、14天感觉亢进,第21天恢复,第28、42天感觉减退。组织学上,神经束在第7天和第14天表现为出血、中性粒细胞浸润和雪旺细胞核丢失。半薄切片显示,雪旺细胞在第14天开始出现空泡变化,到第42天逐渐消退,但髓鞘纤维密度仍然很低。这项研究表明,真菌内酯直接损害神经,并负责无疼痛特征的布鲁里溃疡。在人类病变中,有报道称存在神经炎(Rondini S, 2006),小鼠研究显示“自动截肢”(Addo P, 2005)。为了预防布鲁里溃疡引起的严重畸形,还需要进一步的研究。
{"title":"[Role of mycolactone in the nerve damage of Buruli ulcer (Mycobacterium ulcerans infection)].","authors":"Junichiro En,&nbsp;Norihisa Ishii,&nbsp;Masamichi Goto","doi":"10.5025/hansen.80.5","DOIUrl":"https://doi.org/10.5025/hansen.80.5","url":null,"abstract":"<p><p>Buruli ulcer is a skin disease caused by Mycobacterium ulcerans (M. ulcerans). In this review, we introduce our recent studies and other important works. Lesions of Buruli ulcer are usually painless, despite the extensive tissue necrosis. We have reported that mice inoculated with M ulcerans show nerve degeneration and absence of pain, but the mechanism evoking the nerve damage have not been clarified. In order to define whether mycolactone, a toxic lipid produced by M. ulcerans, can induce nerve damages, we have injected mycolactone A/B to BALB/c mouse footpads. Mycolactone induced footpad swelling, and sensory test showed hyperesthesia on day 7 and 14, recovery on day 21, and hypoesthesia on days 28 and 42. Histologically, nerve bundles showed hemorrhage, neutrophilic infiltration, and loss of Schwann cell nuclei on days 7 and 14. Semithin section studies revealed vacuolar change of Schwann cells started on day 14, which subsided by day 42, but myelinated fiber density remained low. This study suggests that mycolactone directly damages nerves and is responsible for the absence of pain characteristic of Buruli ulcer. In the human lesions, presence of neuritis is reported (Rondini S, 2006), and murine studies showed \"autoamputation\" (Addo P, 2005). In order to prevent the serious deformities evoked by Buruli ulcer, further studies are necessary.</p>","PeriodicalId":35918,"journal":{"name":"Japanese Journal of Leprosy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5025/hansen.80.5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29741566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
[Survey of newly diagnosed Japanese leprosy patients]. 日本麻风病新发病例调查
Q4 Medicine Pub Date : 2011-02-01 DOI: 10.5025/hansen.80.11
Ai Koba, Shuichi Mori, Norihisa Ishii

We aimed to elucidate the patterns and trends of autochthonous leprosy in Japan from 1964 to 2009, to compare them with the findings from other studies of leprosy in decline. Data on registered leprosy cases in Japan in the period 1964-2009 were analysed with reference to trends in case detection, geographical distribution, age at diagnosis, sex, classification and family history. A consistent decline in leprosy case detection was observed in all areas of the country over the period 1964-2009. Highest incidence was consistently in Okinawa. Autochthonous leprosy has not been reported in anyone born in Japan since 1980. Increasing average age and a shift towards lower latitudes were demonstrated throughout the period. Analyses of data on autochthonous cases revealed patterns similar to those reported in other countries with declining leprosy. Okinawa has had the highest incidence of leprosy in all of Japan since the first national survey in 1900. Several possible explanations include the difference of leprosy control history between Okinawa and the rest of Japan, Okinawa's unique geographical condition, large-scale problem of stigma and discrimination against leprosy patients and delayed improvement of socio-economic conditions.

我们的目的是阐明1964年至2009年日本本土麻风的模式和趋势,并将其与其他麻风下降研究的结果进行比较。参照病例发现趋势、地理分布、诊断年龄、性别、分类和家族史,分析了1964-2009年日本麻风登记病例数据。在1964-2009年期间,在全国所有地区观察到麻风病病例检出率持续下降。发病率最高的一直是冲绳。自1980年以来,在日本出生的人没有报告过本地麻风病。在整个期间,平均年龄的增加和向低纬度地区的转移都是显而易见的。对本地病例数据的分析揭示了与其他麻风病发病率下降的国家报告的情况相似的模式。自1900年第一次全国调查以来,冲绳的麻风病发病率一直是日本最高的。一些可能的解释包括冲绳与日本其他地区麻风病控制历史的差异、冲绳独特的地理条件、大规模的麻风病污名化和歧视问题以及社会经济条件的延迟改善。
{"title":"[Survey of newly diagnosed Japanese leprosy patients].","authors":"Ai Koba,&nbsp;Shuichi Mori,&nbsp;Norihisa Ishii","doi":"10.5025/hansen.80.11","DOIUrl":"https://doi.org/10.5025/hansen.80.11","url":null,"abstract":"<p><p>We aimed to elucidate the patterns and trends of autochthonous leprosy in Japan from 1964 to 2009, to compare them with the findings from other studies of leprosy in decline. Data on registered leprosy cases in Japan in the period 1964-2009 were analysed with reference to trends in case detection, geographical distribution, age at diagnosis, sex, classification and family history. A consistent decline in leprosy case detection was observed in all areas of the country over the period 1964-2009. Highest incidence was consistently in Okinawa. Autochthonous leprosy has not been reported in anyone born in Japan since 1980. Increasing average age and a shift towards lower latitudes were demonstrated throughout the period. Analyses of data on autochthonous cases revealed patterns similar to those reported in other countries with declining leprosy. Okinawa has had the highest incidence of leprosy in all of Japan since the first national survey in 1900. Several possible explanations include the difference of leprosy control history between Okinawa and the rest of Japan, Okinawa's unique geographical condition, large-scale problem of stigma and discrimination against leprosy patients and delayed improvement of socio-economic conditions.</p>","PeriodicalId":35918,"journal":{"name":"Japanese Journal of Leprosy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29741567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Review of sentinel surveillance for drug resistance in leprosy conducted by WHO Global Leprosy Programme]. [世卫组织全球麻风规划开展的麻风耐药性哨点监测综述]。
Q4 Medicine Pub Date : 2011-02-01 DOI: 10.5025/hansen.80.71
M Matsuoka
{"title":"[Review of sentinel surveillance for drug resistance in leprosy conducted by WHO Global Leprosy Programme].","authors":"M Matsuoka","doi":"10.5025/hansen.80.71","DOIUrl":"https://doi.org/10.5025/hansen.80.71","url":null,"abstract":"","PeriodicalId":35918,"journal":{"name":"Japanese Journal of Leprosy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29741574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Leprosy in a chimpanzee]. [黑猩猩的麻风病]。
Q4 Medicine Pub Date : 2011-02-01
Norihisa Ishii, Toshifumi Udono, Michiko Fujisawa, Genichi Idani, Kazunari Tanigawa, Tatsuo Miyamura, Koichi Suzuki

Leprosy is suspected to develop after a long period of latency following infection with Mycobacterium leprae (M. leprae) during infancy, but definitive proof has been lacking. We found a rare case of leprosy in a chimpanzee (Pan troglodytes) born in West Africa (Sierra Leone) and brought to Japan around 2 years of age. At 31, the ape started exhibiting pathognomic signs of leprosy. Pathological diagnosis, skin smear, serum anti-phenolic glycolipid-I (PGL-I) antibody, and by PCR analysis demonstrated lepromatous leprosy. Single-nucleotide polymorphism (SNP) analysis verified the West African origin of the bacilli. This occurrence suggests the possibility of leprosy being endemic among wild chimpanzees in West Africa, potentially posing a zoonotic risk.

人们怀疑,在婴儿期感染麻风分枝杆菌(M. leprae)后,经过长时间潜伏期才会发展为麻风,但缺乏明确的证据。我们在一只出生在西非(塞拉利昂)并在大约2岁时被带到日本的黑猩猩(Pan troglodytes)身上发现了一例罕见的麻风病病例。31岁时,这只猿猴开始表现出麻风病的病征。病理诊断、皮肤涂片、血清抗酚类糖脂i (PGL-I)抗体及PCR分析证实为麻风性麻风。单核苷酸多态性(SNP)分析证实该杆菌起源于西非。这一事件表明,麻风病可能在西非野生黑猩猩中流行,可能造成人畜共患风险。
{"title":"[Leprosy in a chimpanzee].","authors":"Norihisa Ishii,&nbsp;Toshifumi Udono,&nbsp;Michiko Fujisawa,&nbsp;Genichi Idani,&nbsp;Kazunari Tanigawa,&nbsp;Tatsuo Miyamura,&nbsp;Koichi Suzuki","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Leprosy is suspected to develop after a long period of latency following infection with Mycobacterium leprae (M. leprae) during infancy, but definitive proof has been lacking. We found a rare case of leprosy in a chimpanzee (Pan troglodytes) born in West Africa (Sierra Leone) and brought to Japan around 2 years of age. At 31, the ape started exhibiting pathognomic signs of leprosy. Pathological diagnosis, skin smear, serum anti-phenolic glycolipid-I (PGL-I) antibody, and by PCR analysis demonstrated lepromatous leprosy. Single-nucleotide polymorphism (SNP) analysis verified the West African origin of the bacilli. This occurrence suggests the possibility of leprosy being endemic among wild chimpanzees in West Africa, potentially posing a zoonotic risk.</p>","PeriodicalId":35918,"journal":{"name":"Japanese Journal of Leprosy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29741569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Molecular mechanism of the acquisition of new-quinolone resistance in Mycobacterium leprae and M. tuberculosis and rapid differentiation methods for resistant bacilli]. 麻风分枝杆菌和结核分枝杆菌获得新喹诺酮类药物耐药性的分子机制及耐药杆菌的快速鉴别方法
Q4 Medicine Pub Date : 2011-02-01 DOI: 10.5025/hansen.80.17
Hyun Kim, Haruka Suzuki, Masanori Matsuoka, Takashi Matsuba, Kazumasa Yokoyama, Chie Nakajima, Yasuhiko Suzuki

Drugs included in new-quinolone are used for the treatment of leprosy with single lesion. These drugs are also known to be effective drugs for the treatment of multi-drug resistant M. tuberculosis. Recent emergence of new-quinolone resistant M. leprae and M. tuberculosis enforced the urgent elucidation of the mode of emergence of new-quinolone resistant strains. In this review, new-quinolone drugs, their mode of action and mechanism of acquisition of resistance by M. leprae and M. tuberculosis were explained. And rapid differentiation methods for resistant bacilli were also introduced.

新喹诺酮类药物中包括的药物用于治疗单一病变的麻风病。这些药物也被认为是治疗多重耐药结核分枝杆菌的有效药物。最近新喹诺酮耐药麻风分枝杆菌和结核分枝杆菌的出现迫使迫切阐明新喹诺酮耐药菌株的出现模式。本文综述了新型喹诺酮类药物及其在麻风分枝杆菌和结核分枝杆菌中获得耐药的作用方式和机制。并介绍了耐药杆菌的快速鉴别方法。
{"title":"[Molecular mechanism of the acquisition of new-quinolone resistance in Mycobacterium leprae and M. tuberculosis and rapid differentiation methods for resistant bacilli].","authors":"Hyun Kim,&nbsp;Haruka Suzuki,&nbsp;Masanori Matsuoka,&nbsp;Takashi Matsuba,&nbsp;Kazumasa Yokoyama,&nbsp;Chie Nakajima,&nbsp;Yasuhiko Suzuki","doi":"10.5025/hansen.80.17","DOIUrl":"https://doi.org/10.5025/hansen.80.17","url":null,"abstract":"<p><p>Drugs included in new-quinolone are used for the treatment of leprosy with single lesion. These drugs are also known to be effective drugs for the treatment of multi-drug resistant M. tuberculosis. Recent emergence of new-quinolone resistant M. leprae and M. tuberculosis enforced the urgent elucidation of the mode of emergence of new-quinolone resistant strains. In this review, new-quinolone drugs, their mode of action and mechanism of acquisition of resistance by M. leprae and M. tuberculosis were explained. And rapid differentiation methods for resistant bacilli were also introduced.</p>","PeriodicalId":35918,"journal":{"name":"Japanese Journal of Leprosy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5025/hansen.80.17","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29741568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Japanese Journal of Leprosy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1